retatrutide nafld nonalcoholic fatty liver disease nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming retatrutide nonalcoholic steatohepatitis trial nash

Instruction videos are very helpful

Patients had higher odds of achieving 10% or greater weight reduction after one year of treatment if they: In addition to looking at the factors that affect a persons weight trajectory, researchers tracked glycemic control in patients who had pre-diabetes at the start of the study

Abdomen (most commonly used): Thigh: Upper Arm: Rotate injection sites weekly to avoid irritation and improve absorption

Holick, New England Journal of Medicine , 2007)

GIP receptor activation improves how the body processes and stores fat, enhances insulin sensitivity beyond what GLP-1 alone achieves, and appears to reduce the inflammatory signaling associated with excess adipose tissue